Avanços Médicos: Marcadores Tumorais Versus Carcinoma de Mama
DOI:
https://doi.org/10.32635/2176-9745.RBC.1995v41n1.2922Keywords:
Tumor Markers, Breast CancerAbstract
The authors propose a review about Tumor Marker CA 15.3 and Breast Cancer. Among different tumor markers that have been used in the Breast Cancer the CA 15.3 has showed the best results. Otherwise, until that moment we can't consider the CA 15.3 as an ideal tumor marker, because it has a low sensibility to diagnosis early disease. New researchs should be done about breast cancer and tumor markers
Downloads
References
SAFI F; KOHLER I; ROTTINGER E; SUHE P; BEGER HG. Comparison of CA 15.3 and CEA in diagnosis and monitoring of breast cancer. lnt J Biol Markers, 1989; 4: 207-14. DOI: https://doi.org/10.1177/172460088900400405
Instituto Nacional do Câncer - Ministério da Saúde. Registro Nacional de Patologia Tumoral. Diagnóstico de Câncer no Brasil 1981/85.
BOCCARDO E; BOMBARDIERI E; ZANARDI S; VALENTI G; ZANABONI F; VALTOLINA M; SEREGNI E; CRIPPA F. Preliminary study on serun leveis of mucinous like câncer antigen (MCA) in patients with breast disease: comparison with CEA. IntJ Biol markers 1991; 6:12-20. DOI: https://doi.org/10.1177/172460089100600103
LOPRINZI Cl_; TORMEY D; RASMUSSEN P; FALKASON G; DAVIS TE; FALKSON HC; CHANG AYC. Prospective evalution of carcinoembionic antigen leveIs and alternating chemotherapeutic regimes in metastatic breast cancer. J Clin Oncol 1986; 4: 46-56. DOI: https://doi.org/10.1200/JCO.1986.4.1.46
MUGHALAW; HORTOBAGYI GN; FRITSCHE HA; BUZDAR AU; YAP HY; BLUMENSCHEIN GR. Serial plasma carcinoembrionic antigen measurement during treatment of metastatic breast cancer. JAMA 1983; 249: 1881-1886. DOI: https://doi.org/10.1001/jama.249.14.1881
FRANCINI G; MONTAGNANI M; PETRIOLI R; PAFFETTI P. MARSILI 5; LEONE V. Comparison between CEA, TPA, CA 15.3 and Hydroxyproline, alkaline phosphatase, whole body retention of 99m-Tc in the foilow-up of bone metastases in breast cancer. Int J Biol Markers 1990; 5: 65-72. DOI: https://doi.org/10.1177/172460089000500203
CAPONIGRO F; IAFFAIOLI RV; PAGLIARULO C; PLACIDE S; FRASCI G; UNGARO B; MATANO E; BIANCOAR. CA 15.3 in human breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembionic antigen (CEA). Int J Biol Markers 1990; 5: 73-6. DOI: https://doi.org/10.1177/172460089000500204
BHATAVDEKAR JM; TRIVEDI SN; SHAH NG; PATEL DD; KARELIA NH; SHUKLA MK; GHOSH N; VORA HH. Comparison of prolactin, CA 15.3 and TPA in breast carcinoma. nt J Biol Markers, 1989; 4: 150-6. DOI: https://doi.org/10.1177/172460088900400304
BIRKMAYER JGD; PALETTA B. New strategies for follow up of breast cancer patients using CEA, TPA, CA 15.3 and CP 50. Human Tumor Markers 1987: 621 -30. DOI: https://doi.org/10.1515/9783110846515-045
MOLINA R; FILELLA X; MENGUAL P; PRATS M; ZANON G; DANIELS M; BALLESTA AM. MOA in patients with breast cancer: correlation with CEA and CA 15.3 Int J Biol Markers 1990; 5: 14-21. DOI: https://doi.org/10.1177/172460089000500103
SORIANO A; ALLENDE MT; VIZOSO F; GGARCIA JF; VIVANCIO J; RUIBAL A. MOA and CA 15.3 serum leveis in non-malignant diseases. Some preliminary results. Letter to the Editor. Int J Biol Markers 1990; 5: 46-47. DOI: https://doi.org/10.1177/172460089000500110
JENSEN JL; MACLEAN GD; SURESH MR; ALMEIDA A; JETTE D; LLOYD 5; BODNAR D; KRANTZ M; LONGENECKER BM. Possible utility of serum determinations of CA 125 and CA 27-29 in breast cancer management. Int J Biol Markers 1990; 6:1-6. DOI: https://doi.org/10.1177/172460089100600101
OMAR YT; BEHBEHANI AE; AL-NAQEEB N; MOTAWY MM; FOUDEH MO; AWWAD AH; NASRALLA MY; SZYMENDERA. Preoperative and longitudinal serum levels of CA 125 and CA 15.3 in patients with breast cancer. Int J Biol Markers 1989; 4: 81-6. DOI: https://doi.org/10.1177/172460088900400204
TORRES M; JIMENEZ-HEFFERNAN A; GARCIA A; VALVERDE A; MATEO A. CA 549 and SP2: new tumor markers in breast cancer. Letter to the Editor. Int J Biol Markers 1990; 5: 97-98. DOI: https://doi.org/10.1177/172460089000500209
DNISTRIAN AM; SCHWATZ MK; GREENBERG EJ; SMITH CA; DORSA R; SCHWARTZ DO. CA 549 as a marker in breast cancer. lntJ Biol Markers 1991; 6:139-43. DOI: https://doi.org/10.1177/172460089100600301
KUTE TE; ZBIERANSKI N; LONG R; POELING K. Proteases and otherprognostic markers in node negative breast cancer; 14th Annual San Antonio Breast Oancer Symposium 1991; Abstract 183.
SCARAMUZZI M; AMOROTTI O; DE PALMA M; FALCHI AM; BALDINI E; DE MARIA D; CASOLO P. Olinical evaluation of CA 15.3 in the post-operatíve foilow-up of breast cancer patients. Int J Biol Markers 1990; 5: 22-26. DOI: https://doi.org/10.1177/172460089000500104
SCARAMUZZI M; AMOROTTI C; DE PALMA M; FALCHI AM; DE MARIA D; CASOLO P. Prognostic significance of CA 15.3 in metastatic breast cancer. Int J Biol Markers 1990; 5: 35-37. DOI: https://doi.org/10.1177/172460089000500107
RHODE PS; SCHULZ KD; STURM G; FRIOK AR; PRINTZ H. CA 15.3 as a tumor marker in breast cancer. Int J Biol markers 1987; 2:135-42. DOI: https://doi.org/10.1177/172460088700200301
VIZOSO F; ALLENDE MT; FUEYO A; VIGAL G; MORAN MG; RUIBAL A. CA 15.3 behavior in cystic breast disease. Letter to the editor. Int J Biol Markers 1989; 4: 181-182. DOI: https://doi.org/10.1177/172460088900400309
BYRNE J; HORGAN P0; ENGLAND S; CALLAGHAN J; GIVEN HF. An evaluation of the usefulness of primary tumour expression of MOA and CA 15.3 as prognostic indicators in breast carcinoma. Eur J of Surg Oncol 1992; 28 (3): 230-34.
HAYES DF; ZURAWSKI VR; KUFE DW. Comparison of circulating CA 15.3 and carcinoembionic antigen leveis in patients with breast cancer. J Olin Oncol 1986; 4: 1542-50. DOI: https://doi.org/10.1200/JCO.1986.4.10.1542
OOLLAZOS; GENOLLA J; RUIBAL A. CA 15.3 in nonmalignant liver diseases. Int J Biol Markers 1991; 6:188-92. DOI: https://doi.org/10.1177/172460089100600309
ZANCO P; ROTA G; SPORTIELLO V; BORSATO N; FERLIN G. Diagnosis of bone and liver metastases in breast cancer comparing tumor markers and imaging techniques. Int J Biol Markers 1989; 4: 103-105. DOI: https://doi.org/10.1177/172460088900400207
